Maze Therapeutics vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision Medicine — Renal, Cardiovascular & Metabolic Diseases
Maze Therapeutics is a clinical-stage precision medicine company using human genetics to develop small-molecule drugs for chronic kidney disease and obesity; lead programs MZE829 and MZE782 in Phase 1/2;
About
Maze Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 by Charles Homcy and headquartered in South San Francisco, California, that uses human genetics as its primary drug discovery engine. The company's approach begins with population-scale genetic data to identify individuals who are naturally protected from diseases like chronic kidney disease (CKD), obesity, and cardiovascular disorders — then designs small-molecule drugs that mimic the protective genetic effect in the broader patient population. This genetics-first model is designed to increase the probability of clinical success by targeting validated mechanisms with demonstrated human proof of concept before any clinical trial begins.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.